Clinical trials: Uterus Cancer
Papillomavirus Type 16/18 Infection, Cervical Intraepithelial Neoplasia
Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
The study will be extended for subjects who received all three doses of vaccine in Finland, Denmark and Estonia to determine long-term safety and immunogenicity of the HPV-16/18 vaccine.
- Trial name
- NCT00337818
- Testing
- Cervarix™
- Where
- Estonia
- Volunteers
- 770 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Heavy Menstrual Bleeding, Uterine Fibroid
LIBERTY 1: Efficacy & Safety Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
The purpose of this study is to determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy…
- Trial name
- NCT03049735
- Testing
- Relugolix, Estradiol/norethindrone acetate
- Where
- 110 sites in United States, Brazil and 4 more
- Volunteers
- 388 people
- Sponsor
- Myovant Sciences GmbH
Uterine Fibroids
A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women
The main objective of this study is to assess safety and efficacy of elagolix compared to placebo in reducing heavy menstrual bleeding (HMB) associated with uterine fibroids in premenopausal women.
- Trial name
- NCT03886220
- Testing
- Elagolix
- Where
- 48 sites in United States, Puerto Rico
- Volunteers
- 82 people
- Sponsor
- AbbVie
Papillomavirus Infections, Cervical Intraepithelial Neoplasia
E7 TCR T Cells for Human Papillomavirus-Associated Cancers
Background: Human papillomavirus (HPV) can cause cervical, throat, anal, and genital cancers. Cancers caused by HPV have an HPV protein called E7 inside of their cells.
- Conditions
- Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ, Vulvar Neoplasms
- Trial name
- NCT02858310
- Testing
- E7 TCR cells, Aldesleukin, Fludarabine
- Where
- 2 sites in United States
- Volunteers
- 224 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Cervical Cancer, Recurrent Vaginal Cancer
Triapine, Cisplatin, and Radiation Therapy in Treating Patients With Cervical Cancer or Vaginal Cancer
This phase II trial is studying how triapine and cisplatin given together with radiation therapy works in treating patients with cervical cancer or vaginal cancer.
- Conditions
- Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Stage IB Cervical Cancer, Stage II Vaginal Cancer
- Trial name
- NCT00941070
- Testing
- triapine, cisplatin, external beam radiation therapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Endometrial Cancer
Papillary Serous Carcinoma of the Endometrium
Primary Objectives: To evaluate the results of Paclitaxel and pelvic radiation in pelvic confined papillary serous carcinoma of the endometrium for both local control and overall survival.
- Trial name
- NCT00515073
- Testing
- Paclitaxel, Pelvic Radiation, Dexamethasone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Cancer
MOtiVating Endometrial Cancer Survivors With Activity Monitors and Tailored Feedback
Overweight and obese endometrial cancer (EC) survivors at the University of North Carolina (UNC) at Chapel Hill will be approached for tailored feedback fitness intervention.
- Trial name
- MOVES (NCT03820024)
- Testing
- Tailored Feedback Messages
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Uterine Fibroids
Pharmacokinetics, Safety and Efficacy Study of Proellex in Pre-menopausal Women With Symptomatic Uterine Fibroids
PK of 25 mg and 50 mg Proellex® administered once daily (QD) over a 4-month period.
- Trial name
- NCT00683917
- Testing
- Proellex 25 mg, Proellex 50 mg, Lupron Depot
- Where
- 4 sites in United States, Mexico
- Volunteers
- 10 people
- Sponsor
- Repros Therapeutics Inc.
Endometrial Cancer
A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
The goal of this clinical research study is to learn if the combination of everolimus, letrozole, and metformin can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01797523
- Testing
- Metformin, Letrozole, Everolimus
- Where
- 6 sites in United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Precancerous Condition
Activating Collaborative CIS Support Via Targeted Provider Mailing
RATIONALE: Receiving a reminder letter from their doctor with questions to ask the Cancer Information Service may be more effective than a standard reminder letter in helping patients who have had an abnormal Pap test keep their…
- Trial name
- NCT00873288
- Testing
- Usual care mailing intervention, CIS support mailing intervention
- Where
- 2 sites in United States
- Volunteers
- 254 people
- Sponsor
- Northwestern University
Cervical Cancer, HPV
Elimisha HPV (Human Papillomavirus)
This research study aims to develop a stigma-responsive educational intervention which includes simplified scripts that provide clear messages about HPV and video aimed at addressing fears and misperceptions from a peer…
- Conditions
- Cervical Cancer, HPV, HIV, Stigma
- Trial name
- NCT05736588
- Testing
- Elimisha HPV
- Where
- Kenya
- Volunteers
- 963 people, healthy volunteers welcome
- Sponsor
- Duke University
Endometrial Cancer
Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer
The goal of this study is to (i) improve detection of sentinel nodes and (ii) reduce additional surgical dissection that is needed in case a sentinel lymph node cannot be detected.
- Trial name
- NCT04511026
- Testing
- Lymphoseek, Single Photon Emission Computed Tomography (SPECT), Indocyanine Green (ICG)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Cervical Intraepithelial Neoplasia, Uterine Cervical Dysplasia
Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix
A-007 is an investigational therapy which may be effective in the treatment of pre-cancerous cervical dysplasia (abnormal cell growth).
- Trial name
- NCT00285207
- Testing
- A007
- Where
- 29 sites in United States
- Volunteers
- 147 people
- Sponsor
- Tigris Pharmaceuticals
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma
Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers
This randomized phase III trial studies radiation therapy and cisplatin with triapine to see how well they work compared to the standard radiation therapy and cisplatin alone in treating patients with newly diagnosed stage IB2…
- Conditions
- Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma
- Trial name
- NCT02466971
- Testing
- Brachytherapy, Cisplatin, External Beam Radiation Therapy
- Where
- 381 sites in United States, Canada and 1 more
- Volunteers
- 450 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer, Nonneoplastic Condition
Vaccine Therapy in Preventing HPV in HIV-Positive Women in India
RATIONALE: Vaccines made from virus proteins may help the body build an effective immune response to prevent cervical cancer. PURPOSE: This pilot study is looking at the side effects of a human papillomavirus vaccine and how well…
- Conditions
- Cervical Cancer, Nonneoplastic Condition, Precancerous Condition
- Trial name
- NCT00667563
- Testing
- quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine, DNA analysis, polymerase chain reaction
- Where
- India
- Volunteers
- 150 people
- Sponsor
- AIDS Malignancy Consortium
Recurrent Endometrial Carcinoma
Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
This phase II trial is studying how well bevacizumab works in treating patients with recurrent or persistent endometrial cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways.
- Trial name
- NCT00301964
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Infections, Papillomavirus
Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects
This study is intended to provide up to a maximum of four years of annual oncogenic human papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study subjects who displayed normal cervical cytology…
- Trial name
- NCT01190176
- Testing
- Gynaecological follow-up, Cervarix
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Endometrial Cancer
Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Primary Objective: To estimate the antitumor activity of the combination of gemcitabine and cisplatin in patients with advanced (stage III or IV) or recurrent endometrial cancer.
- Trial name
- NCT00388154
- Testing
- Gemcitabine, Cisplatin
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Cachexia, Squamous Cell Carcinoma
Testosterone for Treating Cachexia in Patients With Squamous Cell Carcinoma
RATIONALE: Testosterone may lessen weight loss and improve muscle size and strength in patients with cachexia caused by cancer. PURPOSE: This randomized phase I trial is studying whether testosterone administered during standard…
- Trial name
- NCT00878995
- Testing
- Testosterone Enanthate 100 MG/ML
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Neoplasms, Uterine Cervix, Metastatic Cervical Cancer
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
This study is being conducted to compare the efficacy and safety of pazopanib in combination with lapatinib with that of lapatinib alone or pazopanib alone in subjects with metastatic cervical cancer
- Trial name
- NCT00430781
- Testing
- pazopanib (GW786034), lapatinib (GW572016)
- Where
- 63 sites in United States, Argentina and 11 more
- Volunteers
- 228 people
- Sponsor
- GlaxoSmithKline